• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Fact Sheet

Articles Tagged with ''Fact Sheet''

Fact Sheet

NALTREXONE (ReVia, Vivitrol) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone is the first-line medication for alcohol use disorder (AUD) and is also approved for opioid use disorder (OUD).




Read More
Fact Sheet

NALOXONE (Kloxxado, Narcan Nasal Spray, Rextovy, Rezenopy, RiVive, Zimhi) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Nalmefene is an opioid antagonist that has higher affinity for opioid receptors and is more potent and longer acting than naloxone.



Read More
Fact Sheet

Nalmefene (Opvee) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Nalmefene is an opioid antagonist that has higher affinity for opioid receptors and is more potent and longer acting than naloxone.



Read More
Fact Sheet

Lofexidine (Lucemyra) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lofexidine is an alpha-2 agonist (similar to clonidine and guanfacine) that is used to reduce the intensity of opioid withdrawal symptoms.




Read More
Fact Sheet

Buprenorphine/Naloxone (Bunavail, Suboxone, Zubsolv) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine/naloxone is the definitive partial agonist treatment for opioid use disorder (OUD).



Read More
Treatment Algorithm

Opioid Use Disorder Treatment Algorithm

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

  • Opioid Use Disorder Treatment Algorithm



  • Read More
    Fact Sheet

    Blue Light Blocking Glasses Fact Sheet

    January 1, 2026
    Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

    Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

    Blue light blocking glasses are a simple, safe, and remarkably effective adjunctive treatment for bipolar mania and insomnia. 



    Read More
    Fact Sheet

    Weight Gain Fact Sheet

    January 1, 2026
    Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

    Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

    Medication-related weight gain often presents with food cravings and bingeing.




    Read More
    Fact Sheet

    Tremor Fact Sheet

    January 1, 2026
    Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

    Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

    Tremor is a rapid, regular movement of body parts, especially the hands.




    Read More
    Fact Sheet

    Tardive Dyskinesia Fact Sheet

    January 1, 2026
    Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

    Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
    Full Fact Sheet Editorial Information

    Tardive dyskinesia is an involuntary movement disorder that usually appears after months or years of antipsychotic treatment.




    Read More
    Previous 1 2 … 7 8 9 10 11 12 13 14 15 … 56 57 Next
    Try The New AskCarlat AI

    Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

    Available In The Carlat Toolkit
    Free Psychiatry Updates
    The latest unbiased psychiatric information sent to your inbox.
    Specify Your Interests
    Featured Book
    • MFB8e_SpiralCover.png

      Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

      Updated 2026 prescriber's guide.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2782224449.jpg
      General Psychiatry

      Gender Affirming Care: Fall of the House of Hopkins

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.